News

Effectiveness of post-exposure prophylaxis (PEP) with doxycycline for chlamydia and syphilis comes with increase in resistant gonorrhea.

PolyPid has completed its New Drug Application submission to the FDA for D-PLEX100, a novel locally administered antibiotic therapy that significantly reduced surgical site infections in a phase 3 trial and could receive a regulatory decision in early 2027.

The FDA has approved ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older, making it the first and only oral antiviral authorized to help prevent symptomatic infection after exposure.

Modeling of the ACIP recommendation to replace universal birth-dose HepB vaccination with vaccination based on "shared decision" and maternal status shows substantially more maternal screening or vaccinating infants of unscreened mothers will be necessary to mitigate increase in infections.

Traws is studying an oral combination antiviral for hantavirus and Ebola, but no animal or human efficacy data have been reported.

Fluoroquinolones are broadly active and convenient, but Black Box Warnings and resistance concerns have reshaped when and how clinicians should use them.

A 12-month longitudinal analysis of 852 children found two-thirds of those with confirmed SARS-CoV-2 infection reported at least one of 20 post-COVID symptoms, with anxiety and depression equally prevalent in uninfected peers.

Five days of nitrofurantoin was found superior to single-dose fosfomycin for uncomplicated UTI in women, prompting investigators to recommend choosing efficacy over convenience.

In the second episode with Emory’s Gavin Harris, MD, he offers some insights around treating patients with the Andes virus including supportive care as well as investigational antivirals.

At the 2026 MAD-ID/SIDP meeting, Zachary Nelson, PharmD, MPH, BCIDP, discussed how urine-specific breakpoints can improve treatment decisions for urinary tract infections by accounting for drug concentrations in the urinary tract rather than relying solely on traditional blood-level interpretations.

Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses how a coalition of major medical professional societies needed to step in to sue the federal government after sweeping changes to US vaccine policy under Health and Human Services Secretary Robert F. Kennedy Jr. reshaped the CDC’s vaccine advisory process. The medical organizations argued that the evidence-based foundations of public health recommendations had been compromised.

C difficile deaths drop after 2011, but seniors, Black Americans, and rural areas still see higher mortality.

Emory’s Gavin Harris, MD, discusses how getting patients this type of treatment is essential to reducing the severity of disease, as well as adapting the four “I’s” algorithm in dealing with high-consequence infectious disease outbreaks.

The FDA has approved bulevirtide-gmod (Hepcludex), the first approved US therapy for HPDV with no prior treatment options.

In the second episode of our conversation with David Wohl, MD, with the Institute for Global Health and Infectious Diseases at the UNC School of Medicine, he discusses the person-to person transmission, if we expect to see more cases and how it presents, including a serious complication of the virus.

A first-in-human HIV duoCAR-T shows encouraging safety in data presented at ASCGT, with early evidence of viral suppression for up to 2 years after stopping ART.

David Wohl, MD, with the Institute for Global Health and Infectious Diseases at the UNC School of Medicine, provides information on this strain, the quarantine protocols, and what the public should know about when the virus sheds and transmissibility of the disease to others.

The Department of Health and Human Services (HHS) has decided to not move forward with the rewriting of the Advisory Committee on Immunization Practices (ACIP) charter specifying administrative errors.

People with substance use disorder (SUD) face a disproportionate burden of hepatitis infections, underscoring the importance of testing, vaccination, and access to curative treatment during Viral Hepatitis Awareness Month. Stephanie Spivack, MD, offers some insights on the disease burden for this patient population as well as the challenging aspects of getting them into care.

Emily Heil, PharmD, MS, FIDP, BCIDP, AAHIVP, discussed the growing prevalence of metallo-β-lactamase–producing organisms in the United States and highlighted emerging therapeutic strategies designed to overcome increasingly complex antimicrobial resistance mechanisms.

The ongoing Ebola outbreak in Africa has seen the number of cases and deaths rise, and reporting shows some Americans have been exposed to the virus and will likely need quarantining.

Preclinical in vitro and animal models remain essential for establishing antibiotic pharmacokinetic and pharmacodynamic targets, but experts say translating those findings into real-world patient care requires careful consideration of host factors, tissue penetration, and clinical context.

New phase 3 data from the SCORPIO-PEP study showed that a 5-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 after household exposure, highlighting its potential to transform prevention strategies for high-risk populations and future variant-driven surges.

Leaders from SIDP and MAD-ID highlighted their new partnership and announced the launch of the Antimicrobials meeting in 2027, focused on combining cutting-edge science with clinical antimicrobial practice.

Meera Mehta, PharmD, says OPAT programs should move away from a “one-size-fits-all” monitoring model and instead tailor laboratory follow-ups based on patient risk factors, antimicrobial toxicity, and quality-of-life considerations.

SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, explains how the new partnership between SIDP and MAD-ID brings together organizations with shared leadership and values to create a more accessible, collaborative meeting space for infectious diseases pharmacists and related specialties.

David Ha, PharmD, offers insights on how to build out a successful practice-based research project, including developing a strong research question, understanding IRB requirements early, and leveraging reliable institutional data sources and collaborations.

In the second installment of our interview with Andrew Handel, MD, he provides insights on Lyme Disease treatment in the pediatric population.